The US Food and Drug Administration (USFDA) has given its final approval to Glenmark Generics Inc. USA (GGI), the US arm of Glenmark Generics Limited (GGL), to market lithium carbonate capsules in variable strengths.
GGI will market the capsules in dosages of 150 mg, 300 mg and 600 mg.
Lithium is used for treating patients suffering from manic episodes of Bipolar Disorder. Bipolar Disorder, Manic (DSM-III) is equivalent to Manic Depressive illness, Manic, in the older DSM-II terminology.